{"id":"W2598031041","doi":"10.1093/schbul/sbx021.149","title":"111. Efficacy and Safety of MIN-101: A New Drug for the Treatment of Negative Symptoms in Schizophrenia. A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial","year":2017,"lang":"en","type":"article","venue":"Schizophrenia Bulletin","topic":"Pharmacological Receptor Mechanisms and Effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Positive and Negative Syndrome Scale; Tolerability; Placebo; Schizophrenia (object-oriented programming); Clinical Global Impression; Internal medicine; Randomized controlled trial; Clinical endpoint; Adverse effect; Psychology; Psychiatry; Repeated measures design; Clinical trial; Medicine; Psychosis","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009270065,0.0003765355,0.001223849,0.00007273487,0.0002450532,0.00005347026,0.0004380467,0.0002104076,0.00009004011],"category_scores_gemma":[0.000790984,0.0002290724,0.0005159655,0.00004463841,0.0003701849,0.000005706131,0.000128405,0.0001265304,0.000004908401],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002597694,"about_ca_system_score_gemma":0.0001571781,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002649759,"about_ca_topic_score_gemma":0.0001498746,"domain_scores_codex":[0.9979252,0.0002959957,0.0007012207,0.0005198779,0.0001956699,0.0003620389],"domain_scores_gemma":[0.9973149,0.001242849,0.0006602044,0.0005397893,0.00008189457,0.0001603063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9609839,0.0005993297,0.000002719378,0.00002191419,0.0005894344,0.000001618711,0.0001531754,0.00005067476,0.02446245,0.000434389,0.0005184573,0.01218194],"study_design_scores_gemma":[0.9060522,0.003030093,0.0000336243,0.0000504056,0.000362875,0.000001917698,0.00002472797,0.0001295055,0.086133,0.0003268292,0.003637036,0.0002177483],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856761,0.001811816,0.000335505,0.00114224,0.0004741694,0.0102724,0.00003978366,0.000009562847,0.0002384946],"genre_scores_gemma":[0.9938793,0.001448399,0.001649335,0.0000460203,0.0005243213,0.001457562,0.00002625066,0.0000298014,0.0009390233],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06167055,"threshold_uncertainty_score":0.9341303,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02122270088175771,"score_gpt":0.2906111112598571,"score_spread":0.2693884103780994,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}